You are here

  • Home
  • Archive
  • Volume 10, Issue 3
  • Guideline review: British Society of Gastroenterology/UK-PBC Primary Biliary Cholangitis treatment and management guidelines

Article Text

Article menu
Download PDFPDF
Liver
Guideline review
Guideline review: British Society of Gastroenterology/UK-PBC Primary Biliary Cholangitis treatment and management guidelines
  1. Jorn C Goet1,
  2. Gideon M Hirschfield2
  1. 1 Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
  2. 2 Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, Ontario, Canada
  1. Correspondence to Professor Gideon M Hirschfield, Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, ON M5G 2C4, Canada; gideon.hirschfield{at}uhn.ca

Abstract

New guidelines have been produced for the management of primary biliary cholangitis, an infrequent but nonetheless important autoimmune liver disease. We provide a succient commentary and overview of the key features of disease management that arise from these recent guideline recommendations, with a focus on therapy with licensed agents (ursodeoxycholic acid and obeticholic acid) as well as personalised management of disease complications and associated symptoms.

  • cholestasis
  • primary biliary cirrhosis
  • ursodeoxycholic acid
  • obeticholic acid

https://doi.org/10.1136/flgastro-2018-101109

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors Drafting the manuscript: JCG. Drafting and revising the manuscript critically for important intellectual content: GMH.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests GMH has consulted for GSK, Novartis, Cymabay, Intercept, Falk, Gilead.

    • Provenance and peer review Not commissioned; externally peer reviewed.